Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222831
Title: Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study
Author: Bento, Leyre
Gutiérrez García, Antonio Manuel
Martínez, Carmen
Ortí Verdet, María Consejo
Sorribes, Marina
Carolina Caballero, Ana
Peña, Marta
Pérez, Ariadna
Jiménez Ubieto, Ana
Medina, Lucía
Bastos Oreiro, Mariana
Fernández Caldas-González, Paula
Navarro, Belén
Salcedo, Isabel
Abrisqueta, Pau
Español, Ignacio
Cornago Navascues, Javier
Martín Moro, Fernando
García, Lucía
Gómez, Pilar
Varela, María Rosario
Puente, María
Zanabili, Joud
Zudaire, Teresa
Zeberio, Izaskun
Campo, Raquel del
González, Leslie
González, Pedro
Blázquez, Cristina
Rovira, Jordina
Sitges, Marta
Franch Sarto, Mireia
Cabero, Almudena
Mussetti, Alberto
Montoro, Juan
Sampol, Antonia
Sureda, Anna
Caballero, Dolores
Martín García-Sancho, Alejandro
Keywords: Immunosupressió
Limfomes
Immunosuppression
Lymphomas
Issue Date: 31-Mar-2025
Publisher: American Society of Hematology
Abstract: We performed a retrospective multicenter study including 791 patients with relapsed/ refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as >= 3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as >= 3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.
Note: Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2024015415
It is part of: Blood Advances, 2025, vol. 9, num. 13, p. 3281-3292
URI: https://hdl.handle.net/2445/222831
Related resource: https://doi.org/10.1182/bloodadvances.2024015415
ISSN: 2473-9537
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
main (9).pdf1.49 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons